Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital
Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl<sub>4</sub>) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl<sub>4</sub> intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl<sub>4</sub> + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.
Authors
- Joan Clària (ORCID: https://orcid.org/0000-0003-4333-7749)
- Magnus Moeslein
- Inga Grünewald (ORCID: https://orcid.org/0000-0002-2800-4682)
- Maximilian Joseph Brol (ORCID: https://orcid.org/0000-0003-2879-7560)
- Jonel Trebicka (ORCID: https://orcid.org/0000-0002-7028-3881)
- Robert Schierwagen (ORCID: https://orcid.org/0000-0002-2195-3666)
- Pierre‐Emmanuel Rautou (ORCID: https://orcid.org/0000-0001-9567-1859)
- Sophie Lotersztajn (ORCID: https://orcid.org/0000-0002-0053-7807)
- Frank Erhard Uschner (ORCID: https://orcid.org/0000-0002-3760-2887)
- Roger Flores Costa
- Nico Kraus (ORCID: https://orcid.org/0000-0002-5162-1048)
- Marta Duran‐Güell (ORCID: https://orcid.org/0000-0002-3265-395X)
- Sabine Klein (ORCID: https://orcid.org/0000-0001-6691-2895)
- Wenyi Gu
- Eike Fürst
Institutions
- Goethe University Frankfurt (DE)
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- European Foundation for the Study of Chronic Liver Failure (ES)
- University Hospital Münster (DE)
- Hospital Clínic de Barcelona (ES)
- Centre de Recherche sur l'Inflammation (FR)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Cells
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3390/cells13201707
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale